1. Home
  2. SPRO vs FGBI Comparison

SPRO vs FGBI Comparison

Compare SPRO & FGBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.10

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Logo First Guaranty Bancshares Inc.

FGBI

First Guaranty Bancshares Inc.

HOLD

Current Price

$9.94

Market Cap

151.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
FGBI
Founded
2013
1934
Country
United States
United States
Employees
N/A
346
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
151.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
FGBI
Price
$2.10
$9.94
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.6M
65.3K
Earning Date
05-13-2026
04-27-2026
Dividend Yield
N/A
0.44%
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
$567.70
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.80
$4.31
52 Week High
$3.08
$11.02

Technical Indicators

Market Signals
Indicator
SPRO
FGBI
Relative Strength Index (RSI) 38.15 49.06
Support Level $1.93 $9.42
Resistance Level $2.45 $10.03
Average True Range (ATR) 0.11 0.56
MACD -0.00 -0.09
Stochastic Oscillator 29.60 27.62

Price Performance

Historical Comparison
SPRO
FGBI

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.

Share on Social Networks: